PERTH 2
Research type
Research Study
Full title
PERTH 2: Co- design of a home-based monitoring service for cancer patients, carers and healthcare professionals to optimize delivery of systemic cancer therapy
IRAS ID
234137
Contact name
Laurice Edwards
Contact email
Sponsor organisation
Entia Ltd
Duration of Study in the UK
2 years, 11 months, 28 days
Research summary
The study is Sponsored and funded by Entia ltd. This project is a co-design initiative between the investigator team, patients, carers, and health professionals at The Royal Marsden and The Christies NHSFTs.
Entia Ltd, in partnership with The Royal Marsden NHS Foundation Trust, The Christie NHS Foundation Trust, University of Oxford and Imperial College Health Partners, is seeking to develop the world’s first home-based monitoring service to optimize delivery of systemic therapy to cancer patients. As a part of this service, a medical device will be co-designed which is capable of performing a blood count from a small amount of blood. We hope through this technology to improve the experience of receiving treatment for patients and their carers whilst helping healthcare professionals to plan and manage the care of patients undergoing systemic therapy and surgery.
The Royal Marsden NHSFT were responsible for the study design, conduct and data analysis of PERTH part 1 which was the data capturing phase aimed at understanding the patient, carer and clinician experience of routine blood testing during cancer therapy. For PERTH 2, Entia ltd has formatted the study design and will have active input in the group interviews and workshops in relation to the co-design development a final prototype design of a home based full blood count monitoring service.In order to ensure a user-friendly design that meets the end user needs, we propose to develop the device using a co-design model. Patients and carers, along with healthcare professionals and innovators, are all partners in this design process.
Before the device is commercially available, performance evaluation and a final phase clinical trial will be performed to assess the impact of the service on treatment pathways.
REC name
East of England - Cambridge South Research Ethics Committee
REC reference
18/EE/0343
Date of REC Opinion
19 Dec 2018
REC opinion
Further Information Favourable Opinion